We are live on ! Find out more
MVM

Medicxi Ventures Management Portfolio holdings

AUM $982M
1-Year Est. Return 210.17%
This Fund
S&P 500
This Quarter Est. Return
-6.74%
1 Year Est. Return
+210.17%
3 Year Est. Return
+787.54%
5 Year Est. Return
+404.19%
10 Year Est. Return
–
AUM
$313M
AUM Growth
-$43.7M
Cap. Flow
-$13.1M
Cap. Flow %
-4.18%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$13.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTA
1
DELISTED
Centessa Pharmaceuticals
CNTA
$129M 41.24%
19,963,157
– –
PCVX icon
2
Vaxcyte
PCVX
$7.81B
$53.5M 17.09%
1,049,893
-265,542
-20% -$13.1M
PHAT icon
3
Phathom Pharmaceuticals
PHAT
$708M
$39M 12.45%
3,760,869
– –
MRUS
4
DELISTED
Merus
MRUS
$37.7M 12.05%
1,600,000
– –
AURA icon
5
Aura Biosciences
AURA
$725M
$27.3M 8.71%
3,039,892
– –
NAMS icon
6
NewAmsterdam Pharma
NAMS
$3.25B
$26.5M 8.47%
2,869,565
– –

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
FFS
Forge Financial Services Edmond, Oklahoma $987M AUM 14.12% 1-Year Est. Return
PCM
Polymer Capital Management New York $988M AUM 56.33% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return

Medicxi Ventures Management's Q3 2023 Portfolio in Review

As of Q3 2023, Medicxi Ventures Management held 6 positions worth $313M, down 12% from $357M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Medicxi Ventures Management withdrew a net $13.1M in Q3 2023, reducing 1 holding. Its largest reduction was Vaxcyte, cutting an estimated $13.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Medicxi Ventures Management's biggest Q3 2023 reduction was Vaxcyte, cutting an estimated $13.1M.
  • Medicxi Ventures Management's ten largest holdings make up 100% of its $313M portfolio in Q3 2023.
  • Medicxi Ventures Management opened 0 new positions and closed 0 in Q3 2023.
  • Medicxi Ventures Management's portfolio value fell 12% quarter-over-quarter to $313M.

Based on Medicxi Ventures Management's 13F filing for Q3 2023, filed 18 Oct 2023.